Latest Nycomed Stories
CUPERTINO, Calif., May 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2009. Total revenues were $6.2 million for the three months ended March 31, 2009, compared to $6.4 million for the same period in 2008.
BETHESDA, Md., May 6 /PRNewswire-FirstCall/ -- Micromet, Inc.
BETHESDA, Md., April 2 /PRNewswire-FirstCall/ -- Micromet, Inc.
LONDON, March 23 /PRNewswire/ -- The "2008 European Tissue Sealants & Topical Hemostats Product Differentiation Innovation Award" is conferred on Nycomed in recognition of its revolutionary product - TachoSil.
MORRIS PLAINS, N.J., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc.
ZURICH, Switzerland, Oct. 28 /PRNewswire/ -- Nycomed today announced encouraging results from a preliminary analysis of four Phase III trials of Daxas(R) (roflumilast) in the treatment of symptomatic COPD.
MORRIS PLAINS, N.J., Aug. 28, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today reported its recent developments and financial results for the second quarter and six months ended June 30, 2008, and its cash balance as of June 30, 2008.
BETHESDA, Md., Aug. 7 /PRNewswire-FirstCall/ -- Micromet, Inc.
Australia's industry self-regulator Medicines Australia has fined some of the major drug companies over $1.8 million on account of several sales breaches - vilifying rivals' products and lavish spending on educational presentations for doctors.